

### **Intraperitoneal Inoculation of 60As6Luc Cells**

The density of 60As6Luc cells was adjusted to  $1 \times 10^6$  cells per 1 ml phosphate-buffered saline (PBS). In the experimental group, the cell suspension was injected into the abdominal cavity through a 26.5-gauge needle inserted into the central abdomen. In the control group, PBS was injected into the abdominal cavity instead of 60As6Luc cells.

### **Measurement of Tumor Growth Using Luciferase Imaging**

For the measurement of tumor growth, whole-body luciferase imaging with an IVIS imaging system was used to visualize 60As6Luc cells under a 10-min integration time for image acquisition, as described previously.<sup>18</sup> Briefly, mice were injected intraperitoneally with 15 mg D-luciferin potassium salt in 1 ml PBS using a 26.5-gauge syringe. They were then kept anesthetized with isoflurane. The relative tumor metastasis burden was determined using Living Image software (version 2.50, Xenogen).

### **Acute Pancreatitis Model**

Caerulein is an analog of cholecystokinin that leads to acute pancreatitis. Acute pancreatitis was induced by repeatedly injecting mice with caerulein (intraperitoneal administration; 50  $\mu\text{g}/\text{kg}$ ; six times at 1-h intervals).<sup>19,20</sup> Caerulein (Sigma Chemical Co., St. Louis, MO) was dissolved in physiologic saline.

### **Inflammatory Pain Model**

With the mice anesthetized with isoflurane, the plantar surface of the right hind paw was injected with complete Freund's adjuvant (CFA; Mycobacterium tuberculosis; Sigma Chemical Co.) in a volume of 20  $\mu\text{l}$  to create a model of persistent inflammatory pain.<sup>21</sup>

### **Behavioral Test**

Hypersensitivity of the abdomen to mechanical stimulation was quantified by counting the number of withdrawal behaviors (withdrawal of the abdomen away from a von Frey filament, licking of the abdomen as a result of stimulation, or whole-body withdrawal) in response to the application of mechanical stimulation (von Frey filaments with a bending force of 0.02 g) to the abdomen.<sup>19,20</sup> Mice were placed on an increased wire mesh floor and confined under individual overturned black plastic boxes. The von Frey filaments were applied through the mesh floor to different points on the surface of the abdomen. Each filament was applied five times at intervals of 5–10 s, and again after a 1-min rest period for a total of 10 times. Nociceptive behavior was scored as follows: 0 = no response; 1 = immediate slight attempt to escape or light licking or scratching of the stimulated site; 2 = intense withdrawal of the abdomen or jumping. The reported values are the total scores for the responses to 10 challenges. The observer was unaware of the mouse's exper-

imental condition. Behavioral testing was performed on days 14 and 28 after tumor inoculation.

Hunching behavior was examined as described previously with some modifications.<sup>14</sup> Briefly, mice were placed individually in the center of an open field arena and observed for 180 s. The hunching score was the total time (s) the mouse exhibited hunching behavior multiplied by the scoring factor, which was defined according to Sevcik *et al.*<sup>14</sup>: 0 = normal coat luster, displays exploratory behavior; 1 = mild rounded-back posture, displays slightly reduced exploratory behavior, normal coat luster; 2 = severe rounded-back posture, displays considerably reduced exploratory behavior, piloerection, intermittent abdominal contractions. Behavioral testing was performed on days 14 and 28 after tumor inoculation. The observer was unaware of the mouse's experimental condition. Behavioral testing was performed on days 14 and 28 after tumor inoculation.

In the model of CFA-injected inflammatory pain, hypersensitivity of the paw to mechanical stimulation was quantified by counting the number of paw withdrawals in response to the application of mechanical stimulation (von Frey filaments with a bending force of 0.02 g) to the right paw.<sup>21</sup> von Frey filaments were applied to the plantar surface of the hind paw for 3 s (two applications at an interval of at least 5 s). Paw-withdrawal behavior was scored as defined by Narita *et al.*<sup>21</sup>: 0 = no response, 1 = a slow and/or slight response to the stimulus, 2 = a quick withdrawal response away from the stimulus without flinching or licking, 3 = an intense withdrawal response away from the stimulus with brisk flinching and/or licking. The final score for each filament was the average of two scores per paw. Morphine hydrochloride (Sankyo, Tokyo, Japan) was dissolved in physiologic saline. Behavioral testing using morphine was performed at day 28 after tumor inoculation in tumor-bearing mice, at 6 h after the last injection of caerulein (50  $\mu\text{g}/\text{kg}$  and six times) in the acute pancreatitis model, or at 3 days after the injection of CFA in the inflammatory pain model. In the current study, the analgesic effects of morphine or saline were assessed at 30 min (peak time) after subcutaneous injection by an observer who was blind to the type of treatment. The effects of morphine were assessed in terms of the percentage changes from the basal values (before morphine injection).

### **Immunohistochemistry**

Twenty-eight days after the inoculation of tumor cells, mice were deeply anesthetized with isoflurane and perfused with paraformaldehyde (4%; pH 7.4). The spinal cord and dorsal root ganglia (DRG) were removed rapidly and postfixed in 4% paraformaldehyde for 2 h. Sections of the spinal cord (T10–T11) and DRG (T10–T12) were prepared as described previously.<sup>22</sup> Frozen sections of spinal cords and DRGs were cut at 20 and 10  $\mu\text{m}$ , respectively, using a cryostat (Leica CM1510; Leica Microsystems, Heidelberg, Germany). The sections were blocked in normal horse serum (10%) in 0.01 M PBS for 1 h at room temperature. Each

primary antibody was diluted in 0.01 M PBS containing normal horse serum (10%; 1:5,000 c-Fos; Calbiochem, La Jolla, CA), 1:200 substance P (Neuromics, Edia, MN), 1:250  $\mu$ -opioid receptor (MOR; a gift from Masahiko Watanabe, M.D., Ph.D., Hokkaido University Graduate School of Medicine, Sapporo, Japan, October 2010), and anti-MOR antibody against the 1–38 amino acid sequence of the mouse MOR N-terminus<sup>23</sup> and incubated for 1 day at 4°C. They were then rinsed and incubated with each secondary antibody conjugated with Alexa 488 and Rhodamine Red for 2 h at room temperature. The slides were coverslipped with PermaFluor Aqueous mounting medium (Immunon, Pittsburgh, PA), and the fluorescence of immunolabeling was observed by confocal microscopy (LSM510 Meta; Carl Zeiss, Jene, Germany). The anti-MOR antibody used in this study has been shown to be quite specific.<sup>23</sup> The dorsal horn was divided into a superficial layer (L1–2 laminae) and a deep layer (L3–5 laminae), and the number of c-Fos-positive cells was counted in each layer.<sup>24</sup> The cells in 10 randomly selected sections for each marker in each animal were counted, and the average value was determined for each animal. The number of MOR- and substance P-positive profiles in the DRGs was counted as described previously.<sup>25</sup> Briefly, the percentages of MOR- and substance P-positive profiles were determined by counting approximately 2,200 T10–T12 DRG neuronal profiles in tumor-bearing and control mice. We also determined the number of double-positive cells among 500–800 MOR-positive profiles in each mouse. Because we did not use a stereological approach, this quantification may have led to biased estimates of the true numbers of cells and neurons. All counting was performed by an assistant who was blind to the treatment group for the respective sections. To avoid counting neuronal cell bodies twice, for each DRG, we counted sections that were 50  $\mu$ m apart.

### Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR)

Total RNA was isolated from the thoracic 6–13 th and L1–3 DRG using ISOGEN (Nippon Gene Co., Ltd., Tokyo, Japan) according to the manufacturer's instructions. To obtain first-strand complementary DNA, 5  $\mu$ g total RNA was incubated in 100  $\mu$ l buffer containing 10  $\mu$ M dithiothreitol, 2.5 mM MgCl<sub>2</sub>, deoxyriboside-triphosphate mixture, 50 units of reverse transcriptase II (Invitrogen) and oligo(dT)12–18 (Invitrogen). Diluted complementary DNA (2  $\mu$ l) was amplified in a rapid thermal cycler (LightCycler 480; Roche Diagnostics, Mannheim, Germany) in 10  $\mu$ l LightCycler 480 SYBR Green I Master (Roche Diagnostics) and each oligonucleotide. Primer sequences for the genes of interest (substance P, calcitonin gene-related peptide [CGRP], MOR, and glyceraldehyde-3-phosphate dehydrogenase) are shown in table 1. Size and melting curve analyses were performed to confirm that polymerase chain reaction (PCR) amplicons were specific. To quantify the PCR products, LightCycler 480 quantification software was used to

**Table 1.** Primer Sequences for the Mouse Genes Characterized in this Experiment

Gene	Primer
GAPDH	Forward primer: 5' TGTCCTCGTGG ATCTGAC 3'
	Reverse primer: 5' CCTGCTTCACCA CCTTCTTG 3'
Substance P	Forward primer: 5' AAGCCTCAGCAG TTCTTTGG 3'
	Reverse primer: 5' TCTGGCCATGTC CATAAAGA 3'
CGRP	Forward primer: 5' TGCAGGACTATA TGCAGATGAAA 3'
	Reverse primer: 5' GGATCTCTTCTG AGCAGTGACA 3'
MOR	Forward primer: 5' AGCCCTTCCATG GTCACA 3'
	Reverse primer: 5' GGTGGCAGTCTT CATTITGG 3'

CGRP = calcitonin gene-related peptide; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; MOR =  $\mu$ -opioid receptor.

analyze the exponential phase of amplification and the melting curve, as recommended by the manufacturer. The amount of target messenger RNA (mRNA) in the experimental group relative to that in the control was determined from the resulting fluorescence and threshold values ( $C_T$ ) using the  $2^{-\Delta\Delta C_T}$  method.<sup>26</sup> Each experiment was run twice, and samples were run in duplicate. For each sample, a  $\Delta C_T$  value was obtained by subtracting the mean  $C_T$  value for the control gene (glyceraldehyde-3-phosphate dehydrogenase) from that for the gene of interest (substance P, CGRP, and MOR). The average  $\Delta C_T$  value for the control group was then subtracted from the value of each animal in the experimental group to obtain  $\Delta\Delta C_T$ . The fold change relative to the control was then determined by calculating  $2^{-\Delta\Delta C_T}$  for each sample, and the results are expressed as the group mean fold change  $\pm$  SD.


### Statistical Analysis

All data are presented as the mean  $\pm$  standard deviation (SD). All the statistical parameters used in the experiments were calculated using GraphPad PRISM (version 5.0a; GraphPad Software, La Jolla, CA). The statistical significance of differences between groups was assessed with one-way ANOVA followed by the Bonferroni multiple comparisons test or unpaired Student *t* test (two-tailed). A *P* value of  $< 0.05$  was considered statistically significant.

## Results

### Characterization of the Peritoneal Metastasis Model

To analyze the progression of peritoneal dissemination of tumor cells, luciferase gene-transfected 60As6 cells were implanted into the abdominal cavities of mice ( $10^6$  cells/cavity). Photon-counting analyses were performed at the site of dis-



**Fig. 1.** Characterization of the peritoneal metastasis model. Photon-counting analysis of peritoneal dissemination after the intraperitoneal inoculation of 60As6 Luc cells. Scid mice bearing 60As6Luc tumors in the abdominal cavity were anesthetized and subjected to observations after intraperitoneal administration of luciferin (A). Quantitative analysis of the progression of peritoneal disseminated metastasis of tumor cells ( $n = 5$ ). This experiment was repeated three times, and similar results were observed each time (B). Macroscopic evidence of peritoneal dissemination in scid mice bearing tumor cells. There were metastatic lesions in the intestine (C, arrowheads) and the parietal peritoneum (D, arrowheads). Scale bar: 10 mm.

semination at intervals of 7 days. Figure 1A shows a typical example. This method made it possible to observe the same animals over time. A tumor growth curve that reflected the progression of peritoneal dissemination was obtained by plotting the number of photons *versus* time (fig. 1B,  $n = 5$ ). Dissemination to the mesenterium and parietal peritoneum was noted based on the macroscopic appearance of peritoneal dissemination in mice 28 days after inoculation (fig. 1, C and D, arrowheads).

#### **Hypersensitivity to Mechanical Stimulation and Visceral Pain-related Behavior Induced by Peritoneal Carcinomatosis in Mice**

The hypersensitivity to mechanical stimulation in the abdomen was quantified by counting the number of withdrawal behaviors in response to stimulation with von Frey filaments 14 and 28 days after the inoculation of tumor cells (fig. 2A). Twenty-eight days after inoculation, but not 14 days after inoculation, mice with peritoneal dissemination showed a significant increase in the nociceptive score in response to mechanical stimulation ( $P < 0.05$  *vs.* control group, one-way ANOVA followed by the Bonferroni multiple comparisons test, control group:  $n = 5$ , tumor group:  $n = 7$ ). We next examined visceral pain-related behavior, which was assessed in terms of the degree of hunching and the time spent hunching (over 180 s). Hunching behavior has been described previously as a measure of abdominal pain caused by pancreatic cancer in mice.<sup>14</sup> Visceral pain-related behavior was examined at 14 and 28 days after the inoculation of tumor cells (fig. 2B). Spontaneous visceral pain-related behavior became evident at 28 days after inoculation ( $P < 0.05$  *vs.* control


group, one-way ANOVA followed by the Bonferroni multiple comparisons test, each group:  $n = 5$ ).

#### **Changes in c-Fos-positive Cells in the Dorsal Horn of the Spinal Cord Induced by Peritoneal Carcinomatosis**

Spinal cord tissue samples were obtained from animals 28 days after tumor inoculation and from control mice. In control mice, few cFos-positive cells were found in the superficial layer (L1–2 laminae) or deep layer (L3–5 laminae) of the dorsal horn (fig. 3A). In tumor-bearing mice, the number of c-Fos-positive cells was significantly increased in both the superficial and deep layers of the dorsal horn (fig. 3, B and C,  $P < 0.05$  *vs.* control group, one-way ANOVA followed by the Bonferroni multiple comparisons test, each group:  $n = 5$ ).

#### **Changes in the Expression of Substance P, CGRP, and MOR Induced by Peritoneal Carcinomatosis in Mice**

Twenty-eight days after inoculation, the mRNA concentration level of substance P was significantly increased in the DRG of tumor-bearing mice compared with that in control mice, whereas there was no significant difference at 14 days after inoculation (fig. 4A,  $P < 0.05$  *vs.* control group, one-way ANOVA followed by the Bonferroni multiple comparisons test, each group:  $n = 7$ ). In addition, the mRNA concentrations of CGRP in the DRG of tumor-bearing mice were not different from those in the control mice at 14 and 28 days after inoculation (fig. 4B). Under these conditions, 28 days after inoculation, but not 14 days after inoculation, the mRNA concentration of MOR was significantly decreased in the DRG of tumor-bearing mice compared with




**Fig. 2.** Abdominal hypersensitivity to mechanical stimulation and visceral pain-related behavior induced by peritoneal carcinomatosis in mice. Hypersensitivity was quantified by counting the number of withdrawal behaviors in response to mechanical stimulation at 14 and 28 days after the inoculation of tumor cells (A). Visceral pain-related behavior was assessed in terms of the degree of hunching and time spent hunching (over 180 s) at 14 and 28 days after the inoculation of tumor cells (B). Each column represents the mean  $\pm$  SD. \*  $P < 0.05$  versus control group, one-way ANOVA followed by the Bonferroni multiple comparisons test.

that in control mice (fig. 4C,  $P < 0.05$  vs. control group, one-way ANOVA followed by the Bonferroni multiple comparisons test, each group:  $n = 7$ ).

#### Changes in MOR in Substance P-positive DRG Neurons Induced by Peritoneal Carcinomatosis in Mice


The expression patterns of MOR in DRG neurons were determined at 28 days after inoculation in control and tumor-bearing mice. In the T10–12 DRGs of control mice, MOR-positive profiles were seen in  $39.0 \pm 1.6\%$  of all neurons (fig. 5A), which was significantly greater than the value in tumor-bearing mice ( $26.7 \pm 2.9\%$ , fig. 5, B and C,  $P < 0.05$  vs. control group, unpaired Student  $t$  test (two-tailed), each group:  $n = 3$ ). In addition, the percentage of substance P-positive profiles in tumor-bearing mice ( $24.2 \pm 3.6\%$ ) was significantly greater than that in control mice ( $15.4 \pm 1.1\%$ , fig. 5, D, E, and F,  $P < 0.05$  vs. control group, unpaired Student  $t$  test (two-tailed), each group:  $n = 3$ ). We next investigated the change in the colocalization of MOR with substance P (arrowhead). Although  $69.6 \pm 4.9\%$  of substance P-positive profiles in control mice were also MOR-positive, tumor inoculation significantly decreased this percentage ( $38.7 \pm 0.9\%$ , fig. 5G,  $P < 0.05$  vs. control group, unpaired Student  $t$  test [two-tailed], each group:  $n = 3$ ).



**Fig. 3.** Changes in c-Fos-positive cells in the dorsal horn of the spinal cord induced by peritoneal carcinomatosis. c-Fos expression in a control mouse (A) and in the dorsal horn of a tumor-bearing mouse on day 28. Inset is a high magnification image of the squared area (B). Increases in c-Fos-positive cells were observed in the superficial layer (L1–2 laminae) and the deep layer (L3–5 laminae) of the dorsal horn in tumor-bearing mice (C). The results represent the means  $\pm$  SD. \*  $P < 0.05$  versus control group, one-way ANOVA followed by the Bonferroni multiple comparisons test. Scale bar:  $50 \mu\text{m}$ .

#### Effect of Systemic Administration of Morphine on the Nociceptive Behavior in Response to Mechanical Stimulation in Tumor-bearing Mice, Caerulein-injected Mice, and CFA-injected Mice

Repeated treatment with caerulein (six injections,  $50 \mu\text{g}/\text{kg}$ ) resulted in abdominal hypersensitivity to mechanical stimulation, indicating that caerulein-injected mice exhibited an acute pancreatitis pain-like state.<sup>19,20</sup> On the other hand, the latency of paw withdrawal induced by mechanical stimulation was reduced dramatically by the intraplantar injection of a CFA solution into the mouse hind paw.<sup>21</sup> In tumor-bearing, caerulein-injected, and CFA-injected mice, subcutaneous injection of saline did not have any effect on the nociceptive score. In caerulein-injected and CFA-injected mice, subcutaneous injection of morphine reduced the nociceptive score in a dose-dependent manner in response to mechanical stimulation compared with that in mice injected with saline ( $P < 0.05$ ,  $1 \text{ mg}/\text{kg}$ :  $68.4 \pm 17.5\%$  of the basal value,  $3 \text{ mg}/\text{kg}$ :  $43.8 \pm 21.4\%$  of the basal value,  $5 \text{ mg}/\text{kg}$ :  $22.2 \pm 10.1\%$  of the basal value, caerulein-saline group [ $n = 5$ ] vs. caerulein-morphine group [ $n = 6$ ];  $P < 0.05$ ,  $3 \text{ mg}/\text{kg}$ :  $42.9 \pm 13.1\%$  of the basal value,  $5 \text{ mg}/\text{kg}$ :  $9.5 \pm 14.9\%$  of the basal value, CFA-saline group [ $n = 6$ ] versus CFA-mor-



**Fig. 4.** Transcriptional regulation of substance P, calcitonin gene-related peptide (CGRP), and  $\mu$ -opioid receptor (MOR) in the dorsal root ganglia (DRG) induced by peritoneal carcinomatosis. Expression of substance P (A), CGRP (B), and MOR (C) in the DRG of tumor-bearing mouse on days 14 and 28. Real-time reverse transcription polymerase chain reaction was carried out on messenger RNA (mRNA) obtained from thoracic 6–13 th and L1–3 DRG. The mRNA concentrations were normalized to those for glyceraldehyde-3-phosphate dehydrogenase (housekeeping gene), and the results are presented as the means  $\pm$  SD. \* $P < 0.05$  versus control group, one-way ANOVA followed by the Bonferroni multiple comparisons test.

phine group [ $n = 7$ ], one-way ANOVA followed by the Bonferroni multiple comparisons test). In tumor-bearing mice, subcutaneous injection of morphine at a dose of 3 mg/kg, which significantly reduced the nociceptive score in both caerulein-injected and CFA-injected mice, did not have any effect on the nociceptive score. In contrast, higher doses of morphine (5 and 10 mg/kg) produced a significant reduction in the nociceptive score ( $P < 0.05$ ,  $52.8 \pm 15.6\%$  and  $39.2 \pm 9.3\%$  of the basal value, respectively, tumor-saline group [ $n = 5$ ] vs. tumor-morphine group [ $n = 5$ ], one-way ANOVA followed by the Bonferroni multiple comparisons


test). However, the effect of morphine was less in tumor-bearing mice than in caerulein-injected and CFA-injected mice (fig. 6).

## Discussion

Patients with cancer in the advanced stages, especially those with bone metastasis and cancerous peritonitis, endure significant pain. Patients with tumors involving bone destruction and nerve damage are particularly likely to experience severe pain.<sup>27–29</sup> Although published guidelines for pain management are available, the routine use of this treatment does not always alleviate this kind of pain.<sup>3,29,30</sup> Cancer pain often is treated by higher doses of morphine, which can be accompanied by side effects, including sedation, respiratory depression, and interference with gastrointestinal motility, and often provides only incomplete relief. Not surprisingly, novel, more effective analgesics are needed for the treatment of severe opioid-resistant cancer pain, such as abdominal pain caused by cancerous peritonitis.


In this study, we developed a novel mouse model for abdominal pain caused by cancerous peritonitis. Generally, it is difficult to monitor growth and subsequent progression of tumors to cancerous peritonitis, unlike with subcutaneous tumors. In the current study, we observed the progression of dissemination in real-time using luciferase gene-transfected cells and an *in vivo* photon-counting analysis. The level of emitted photon intensity gradually increased over time after tumor cell inoculation, and the intensity level at 28 days after tumor inoculation was approximately 10-fold that at 7 days. Mice with peritoneal dissemination showed dramatic increases in both their nociceptive scores in response to mechanical stimulation and visceral pain-related behavior at 28 days after the inoculation of tumor cells. However, these pain-like behaviors were not observed 14 days after inoculation, suggesting that this abdominal hypersensitivity is observed predominantly in mice at the relatively late stage of cancerous peritonitis.

Nociceptors relay information from the periphery to the spinal cord, where they target secondary neurons in the superficial (L1–2 laminae) and deep layers (L3–5 laminae) of the dorsal horns.<sup>31</sup> Some of these secondary neurons are projection neurons that then pass this nociceptive information to the central nervous system.<sup>31</sup> To visually identify the changes in the activity of spinal neurons related to pain in this model, we observed the changes in the immunoreactivity of c-Fos, an immediate-early gene that is widely used in pain research as a marker for neuronal activation.<sup>32–34</sup> At 28 days after inoculation, there was an increase in c-Fos-positive cells in both the superficial and deep layers of the spinal cord. Second-order neurons in the spinal cord that receive visceral afferent input are located principally in the superficial spinal laminae, deeper in L5 and L10 laminae. Some studies have shown that somatic structures send afferents to L1–3 laminae and to deep L4 and L5 laminae.<sup>35,36</sup> Taken together, the current findings suggest that the progressive insult of the



**Fig. 5.** Expression of  $\mu$ -opioid receptor (MOR) in the dorsal root ganglia (DRG) of a control mouse (A) and a tumor-bearing mouse (B). Expression of substance P in the DRG of a control mouse (D) and a tumor-bearing mouse (E). Percentage of total cells expressing MOR (C), substance P (F), or MOR/substance P (G) in the DRG of control mice and tumor-bearing mice. The results are presented as the means  $\pm$  SD. \*  $P < 0.05$  versus control group, unpaired Student  $t$  test (two-tailed). Scale bar: 20  $\mu$ m.

peripheral nerve on the mesenterium and parietal peritoneum caused by tumor growth may result in the progression of wide-ranging pain accompanied by an increase in c-Fos-positive cells in the spinal cord.



**Fig. 6.** Effects of systemic morphine treatment on the nociceptive scores in tumor-bearing (circles), caerulein-injected (squares), or complete Freund's adjuvant (CFA)-injected mice (triangles). Six hours after the last injection of caerulein (six injections, 50  $\mu$ g/kg) or 3 days after CFA-injection, groups of mice were treated with subcutaneous morphine (1, 3, and 5 mg/kg). Twenty-eight days after the inoculation of tumor cells, groups of mice were treated with subcutaneous morphine (3, 5, and 10 mg/kg). The behavioral test was performed 30 min after the injection of morphine. Hypersensitivity to mechanical stimulation was quantified by counting the number of withdrawal behaviors in response to mechanical stimuli. The results are presented as the means  $\pm$  SD. #  $P < 0.05$ , caerulein-saline group versus caerulein-morphine group. \*  $P < 0.05$ , CFA-saline group versus CFA-morphine group. \*  $P < 0.05$ , tumor-saline group versus tumor-morphine group, one-way ANOVA followed by the Bonferroni multiple comparisons test.

A variety of neurochemical and other markers have been used to characterize sensory neurons as nociceptive. The neuropeptides substance P and CGRP are considered to be markers of putative nociceptive DRG neurons.<sup>31</sup> In the current model, we observed a dramatic increase in the expression of substance P but not CGRP in the DRG of mice with peritoneal dissemination. Consistent with the data, the percentage of substance P-positive neurons apparently was increased in tumor-bearing mice. Substance P and CGRP have been reported to be up-regulated in both sensory neurons and primary afferent terminals in models of inflammatory pain.<sup>37,38</sup> In contrast, these neurotransmitters have been shown to be down-regulated in the spinal cord of models of nerve injury.<sup>39,40</sup> There was no significant change in the expression of these peptides in a murine model of bone cancer pain.<sup>41</sup> Substance P is abundant in visceral primary afferents (more than 80%),<sup>42</sup> and neurokinin1 receptor knockout mice show a significant deficit in visceral nociceptive perception.<sup>43,44</sup> Furthermore, inflammatory cytokine and neurotrophic factors can induce the increased production of substance P and neurokinin1 receptors.<sup>45</sup> These data support the idea that inflammatory cytokine and neurotrophic factors released by damaged peripheral nerve and/or tumor cells may promote the novel synthesis of substance P in the DRG of mice with peritoneal carcinomatosis. This phenomenon would correspond to the abdominal pain caused by the peritoneal dissemination of cancer cells in mice.

Another key finding in the current study was that peritoneal carcinomatosis decreased the mRNA expression of MOR in the DRG. In addition to MOR mRNA, the results of an immunohistochemical analysis revealed that the percentage of substance P-positive neurons that also were MOR-positive was decreased remarkably in the DRG of tumor-bearing mice. In relation to the down-regulation of MOR in the DRG, the dose-response curve for the antihy-

peralgesic effect of morphine against tumor-dependent pain was shifted to the right compared with that found in mice with either caerulein-induced visceral pain or CFA-induced inflammatory pain. Changes in MOR expression in the DRG have been shown in several pain models. Models of peripheral nerve injury have shown a dramatic decrease in MOR expression in the DRG, and such injuries reduce the effects of MOR agonists.<sup>46-49</sup> On the other hand, peripheral inflammation increases MOR expression in the dorsal horn of the spinal cord and the DRG, which are responsible for enhancing the effects of MOR agonists.<sup>50,51</sup> Luger *et al.*<sup>52</sup> and Yamamoto *et al.*<sup>25</sup> showed that higher doses of morphine were required to treat bone cancer pain than to treat inflammatory pain. It has been proposed that an increase in MOR mRNA production increases an opioid's efficacy at individual nociceptors.<sup>53</sup> Taken together, the current findings strongly support the idea that the decreased MOR expression in substance P-positive DRG may correspond to the reduction in the morphine-induced antinociception or analgesia in mice with peritoneal carcinomatosis.

In conclusion, mice with peritoneal carcinomatosis exhibit hypersensitivity to mechanical stimulation and visceral pain-like behavior, which is accompanied by the up-regulation of substance P and the down-regulation of MOR. This newly developed model may be important for studying the pathogenesis of abdominal pain caused by cancerous peritonitis.

The authors thank Masahiko Watanabe, M.D., Ph.D., Professor, Department of Anatomy and Embryology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, for the specific anti-MOR antibody.

## References

- van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J: Prevalence of pain in patients with cancer: A systematic review of the past 40 years. *Ann Oncol* 2007; 18:1437-49
- Hall EJ, Sykes NP: Analgesia for patients with advanced disease: I. *Postgrad Med J* 2004; 80:148-54
- Portenoy RK: Treatment of cancer pain. *Lancet* 2011; 377: 2236-47
- WHO: Cancer Pain Relief, 2nd edition. Geneva, World Health Organisation, 1996
- Jayne D: Peritoneal Carcinomatosis: A Multidisciplinary Approach. New York, Springer Science Business Media, 2006, pp 21-33
- Cervero F: Sensory innervation of the viscera: Peripheral basis of visceral pain. *Physiol Rev* 1994; 74:95-138
- Pacharinsak C, Beitz A: Animal models of cancer pain. *Comp Med* 2008; 58:220-33
- Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW: Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. *J Neurosci* 1999; 19:10886-97
- Lindsay TH, Jonas BM, Sevcik MA, Kubota K, Halvorson KG, Ghilardi JR, Kuskowski MA, Stelow EB, Mukherjee P, Gendler SJ, Wong GY, Mantyh PW: Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. *Pain* 2005; 119:233-46
- Nagamine K, Ozaki N, Shinoda M, Asai H, Nishiguchi H, Mitsudo K, Tohno I, Ueda M, Sugiura Y: Mechanical allodynia and thermal hyperalgesia induced by experimental squamous cell carcinoma of the lower gingiva in rats. *J Pain* 2006; 7:659-70
- Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW: Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. *Nat Med* 2000; 6:521-8
- Niiyama Y, Kawamata T, Yamamoto J, Furuse S, Namiki A: SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. *Br J Anaesth* 2009; 102:251-8
- Furuse S, Kawamata T, Yamamoto J, Niiyama Y, Omote K, Watanabe M, Namiki A: Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain. *ANESTHESIOLOGY* 2009; 111:173-86
- Sevcik MA, Jonas BM, Lindsay TH, Halvorson KG, Ghilardi JR, Kuskowski MA, Mukherjee P, Maggio JE, Mantyh PW: Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer. *Gastroenterology* 2006; 131: 900-10
- Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. *Pain* 1983; 16:109-10
- Yanagihara K, Tanaka H, Takigahira M, Ino Y, Yamaguchi Y, Toge T, Sugano K, Hirohashi S: Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. *Cancer Sci* 2004; 95:575-82
- Yanagihara K, Takigahira M, Tanaka H, Komatsu T, Fukumoto H, Koizumi F, Nishio K, Ochiya T, Ino Y, Hirohashi S: Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. *Cancer Sci* 2005; 96:323-32
- Yanagihara K, Takigahira M, Takeshita F, Komatsu T, Nishio K, Hasegawa F, Ochiya T: A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. *Cancer Res* 2006; 66:7532-9
- Kawabata A, Matsunami M, Tsutsumi M, Ishiki T, Fukushima O, Sekiguchi F, Kawao N, Minami T, Kanke T, Saito N: Suppression of pancreatitis-related allodynia/hyperalgesia by proteinase-activated receptor-2 in mice. *Br J Pharmacol* 2006; 148:54-60
- Takemura Y, Furuta S, Hirayama S, Miyashita K, Imai S, Narita M, Kuzumaki N, Tsukiyama Y, Yamazaki M, Suzuki T, Narita M: Upregulation of bradykinin receptors is implicated in the pain associated with caerulein-induced acute pancreatitis. *Synapse* 2011; 65:608-16
- Narita M, Shimamura M, Imai S, Kubota C, Yajima Y, Takagi T, Shiokawa M, Inoue T, Suzuki M, Suzuki T: Role of interleukin-1 $\beta$  and tumor necrosis factor- $\alpha$ -dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice. *Neuroscience* 2008; 152: 477-86
- Narita M, Suzuki M, Narita M, Niikura K, Nakamura A, Miyatake M, Aoki T, Yajima Y, Suzuki T: Involvement of spinal metabotropic glutamate receptor 5 in the development of tolerance to morphine-induced antinociception. *J Neurochem* 2005; 94:1297-305
- Kasai S, Yamamoto H, Kamegaya E, Uhl GR, Sora I, Watanabe M, Ikeda K: Quantitative detection of  $\mu$  opioid receptor: Western blot analyses using  $\mu$  opioid receptor knockout mice. *Curr Neuropharmacol* 2011; 9:219-22
- Shimoyama M, Tatsuoka H, Ohtori S, Tanaka K, Shimoyama N: Change of dorsal horn neurochemistry in a mouse model of neuropathic cancer pain. *Pain* 2005; 114:221-30
- Yamamoto J, Kawamata T, Niiyama Y, Omote K, Namiki A: Down-regulation of  $\mu$  opioid receptor expression within

- distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. *Neuroscience* 2008; 151:843-53
26. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the  $2(-\Delta\Delta C(T))$  method. *Methods* 2001; 25:402-8
  27. Mercadante S: Malignant bone pain: Pathophysiology and treatment. *Pain* 1997; 69:1-18
  28. Vecht CJ: Cancer pain: A neurological perspective. *Curr Opin Neurol* 2000; 13:649-53
  29. Forman AD: Peripheral neuropathy and cancer. *Curr Oncol Rep* 2004; 6:20-5
  30. Cherny NI: How to deal with difficult pain problems. *Ann Oncol* 2005; 16(Suppl 2):ii79-87
  31. Todd AJ, Koerber R: Neuroanatomical substrates of spinal nociception. Wall and Melzack's Textbook of Pain, 5th edition. London, Elsevier, 2006, pp 73-90
  32. Ma QP, Woolf CJ: Basal and touch-evoked fos-like immunoreactivity during experimental inflammation in the rat. *Pain* 1996; 67:307-16
  33. Coggeshall RE: Fos, nociception and the dorsal horn. *Prog Neurobiol* 2005; 77:299-352
  34. Castellanos DA, Daniels LA, Morales MP, Hama AT, Sagen J: Expansion of formalin-evoked Fos-immunoreactivity in rats with a spinal cord injury. *Neurosci Res* 2007; 58:386-93
  35. Craig AD, Kniffki KD: Spinothalamic lumbosacral lamina I cells responsive to skin and muscle stimulation in the cat. *J Physiol* 1985; 365:197-221
  36. Mense S: Nociception from skeletal muscle in relation to clinical muscle pain. *Pain* 1993; 54:241-89
  37. Ahmed M, Bjurholm A, Schultzberg M, Theodorsson E, Kricbergs A: Increased levels of substance P and calcitonin gene-related peptide in rat adjuvant arthritis: A combined immunohistochemical and radioimmunoassay analysis. *Arthritis Rheum* 1995; 38:699-709
  38. Donnerer J, Schuligoi R, Stein C: Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: Evidence for a regulatory function of nerve growth factor *in vivo*. *Neuroscience* 1992; 49:693-8
  39. Nahin RL, Ren K, De León M, Ruda M: Primary sensory neurons exhibit altered gene expression in a rat model of neuropathic pain. *Pain* 1994; 58:95-108
  40. Sommer C, Myers RR: Neurotransmitters in the spinal cord dorsal horn in a model of painful neuropathy and in nerve crush. *Acta Neuropathol* 1995; 90:478-85
  41. Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, Clohisy DR, Mantyh PW: Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. *Neuroscience* 2000; 98:585-98
  42. Perry MJ, Lawson SN: Differences in expression of oligosaccharides, neuropeptides, carbonic anhydrase and neurofilament in rat primary afferent neurons retrogradely labelled *via* skin, muscle or visceral nerves. *Neuroscience* 1998; 85:293-310
  43. Muñoz M, Coveñas R: NK-1 receptor antagonists: A new paradigm in pharmacological therapy. *Curr Med Chem* 2011; 18:1820-31
  44. Laird JM, Olivar T, Roza C, De Felipe C, Hunt SP, Cervero F: Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. *Neuroscience* 2000; 98:345-52
  45. Tuluc F, Lai JP, Kilpatrick LE, Evans DL, Douglas SD: Neurokinin 1 receptor isoforms and the control of innate immunity. *Trends Immunol* 2009; 30:271-6
  46. Lee YW, Chaplan SR, Yaksh TL: Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. *Neurosci Lett* 1995; 199:111-4
  47. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F: Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. *Neurosci Lett* 1995; 199:83-6
  48. Kohno T, Ji RR, Ito N, Allchorne AJ, Befort K, Karchewski LA, Woolf CJ: Peripheral axonal injury results in reduced  $\mu$  opioid receptor pre- and post-synaptic action in the spinal cord. *Pain* 2005; 117:77-87
  49. Narita M, Imai S, Nakamura A, Ozeki A, Asato M, Rahmadi M, Sudo Y, Hojo M, Uezono Y, Devi LA, Kuzumaki N, Suzuki T: Possible involvement of prolonging spinal  $\mu$ -opioid receptor desensitization in the development of antihyperalgesic tolerance to  $\mu$ -opioids under a neuropathic pain-like state. *Addict Biol* 2011 [Epub ahead of print]
  50. Ji RR, Zhang Q, Law PY, Low HH, Elde R, Hökfelt T: Expression of  $\mu$ -,  $\delta$ -, and  $\kappa$ -opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. *J Neurosci* 1995; 15:8156-66
  51. Maekawa K, Minami M, Masuda T, Satoh M: Expression of  $\mu$ - and  $\kappa$ -, but not  $\delta$ -, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats. *Pain* 1996; 64:365-71
  52. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, Rathbun M, Clohisy DR, Honore P, Yaksh TL, Mantyh PW: Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer *versus* inflammatory pain. *Pain* 2002; 99:397-406
  53. Silbert SC, Beacham DW, McCleskey EW: Quantitative single-cell differences in  $\mu$ -opioid receptor mRNA distinguish myelinated and unmyelinated nociceptors. *J Neurosci* 2003; 23:34-42



# ここまでわかってきた漢方薬の 「なぜ効くの？」と「本当に効くの？」

—科学的エビデンスに基づいた、  
がん患者のQOLを高める漢方薬の効果—

独立行政法人国立がん研究センター研究所がん患者病態生理研究分野分野長  
上園 保仁

## はじめに

2011年12月発行の本誌22巻2号におきまして、基礎医学セミナー「がん患者の症状緩和に役立つ漢方薬—漢方薬の有効性を示す、臨床につながる基礎研究—」を紹介いたしました<sup>1)</sup>。そこから1年が経過し、漢方薬ががん患者の生活の質(quality of life; QOL)を改善させる可能性のあることが基礎研究ならびに臨床研究を通してさらに進展いたしました。われわれもこの1年、漢方薬の「なぜ効くの？」について基礎研究を行い、またそれを臨床研究につなげ、「本当に効くの？」を明らかにするための臨床試験を開始しました。本稿では、漢方薬の「なぜ効くの？」と「本当に効くの？」を明らかにするための「漢方薬の基礎研究と臨床研究の最前線」を紹介いたします。

がん患者は、がん自体に加えて手術療法、化学療法、放射線療法などの副作用などにより倦怠感、痛み、しびれ、嘔気・嘔吐など、多くのQOLを低下させる症状に悩まされています。個々の症状について症状緩和を行い、結果として患者の全体症状が和らげばよいのですが、なかなかそういかないのが現実です。日本には、病を個別に診るのではなく人を全体的に診て症状を和らげる「漢方薬」があります。近年、科学的なアプローチにより漢方薬の作用メカニズムの一端が次々と解明されてきました。それらの研究の進展により、今後がん患者のもつさまざまな症状緩和に「漢方薬」が積極的に役立つ可能性が生まれつ

つあると考えています。世界中で、「西洋薬」に加えて保険でカバーされた「漢方薬」を使える国は日本しかありません。

## 漢方薬とは？ 漢方薬の位置づけは？

漢方薬「Kampo Medicine」は、中国で生まれ発展した中医学(生薬(中薬)をベースに治療を組み立てたもの)を、日本の気候風土や日本人の体質にあわせて17世紀江戸時代に独自に発展させて生まれた薬剤です。1967年に漢方薬は公的医療保険の適用となり、その適用数も徐々に増え、現在では148種の漢方薬が保険収載薬として医療現場で使えるようになっています。これまで漢方薬を使用されてきた先生方の経験に基づいた治療成績により、多くの病人の体質ならびに症状にあわせた漢方処方が可能となっています。くわえて、漢方薬の成分がいかにして一つひとつの症状を抑えるのか？ どのようにして効くのか？ の科学的根拠が明らかとなってきました。特に一部の漢方薬(大建中湯)については、米国食品医薬品局(Food and Drug Administration; FDA)により臨床治験薬として承認され、これまでに終了した分も含めて5本の臨床試験が米国内で行われています(表1)。欧米諸国ではいわゆる科学的根拠のない薬剤についてはその使用が認められないのが通常です。しかし、日本の漢方薬に限っていえば、これまで日本で積み重ねられてきた安全性、ならびに科学的アプローチによる基礎研究の結果をふまえ、さらに臨床研究においても

表1. 米国における大建中湯(TU-100)を用いた臨床研究(2012年9月現在)

米国FDAに臨床試験を認可された漢方薬
術後イレウス患者におけるTU-100の忍容性試験 —試験終了
術後イレウス患者における腸管機能ならびに腸内食物通過時間におけるTU-100の効果試験 —試験終了
クローン病患者におけるTU-100の安全性ならびに効果試験—患者登録中
機能性便秘症患者におけるTU-100の効果確認試験—患者登録中
便秘女性における大腸機能、小腸機能に関する効果試験—患者登録中

(Clinical Trials. govより和訳・引用)

質の高い試験が行われていると米国FDAは判断し、米国での臨床試験にゴーサインを出しました。試験の結果、科学的根拠をもとに有効であると判断されれば、漢方薬は日本発のオリジナル薬として、また米国初の合剤(漢方薬は少なくとも2種類以上の生薬から成ります)として米国ではじめて認可され用いられることとなります。大建中湯の米国での臨床試験への道筋を丹念に築いてこられた旭川医科大学消化器病態外科学客員准教授の河野透先生(札幌東徳洲会病院先端外科センター長)の、漢方薬を用いたこの数年の実験結果が一流雑誌に掲載されており、このことも米国FDAの判断に大きく寄与したと思われます<sup>2)-4)</sup>。以前にも述べさせていただきましたが、漢方薬が欧米で注目されるに至ったのは、世界的にも有名な外科の雑誌「Surgery」に、漢方薬はエビデンス(科学的に検証された確かな効果)があるということで「Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines ; is it time yet? (日本の伝統的薬物、「漢方薬」の補完代替医療からの脱出：今その時期か?)」という刺激的なタイトルの漢方総説が2009年に掲載されたことによりま




図1. 「痛みゼロのがん治療」 向山雄人 著(公益財団法人がん研究会有明病院緩和治療科部長)  
(文献6)より

- がん治療法
1. 外科治療
  2. 抗がん剤治療
  3. 放射線治療
  4. 免疫療法
  5. がん緩和ケア

す<sup>5)</sup>。「Surgery」編集委員長のメイヨー・クリニック外科教授、Michael G. Sarr博士も、「Kampo Medicineは、もはや補完代替医療(CAM)の1つではなく、科学的なエビデンスに基づいた薬物である」という立場に変わられました。

### さらに明らかになってきた漢方薬の作用メカニズム

漢方薬のなかには、がん患者のもつさまざまな症状のそれぞれに対応するようなものが現れはじめています。

がんの治療には外科手術、放射線療法、抗がん剤による治療、最近では免疫療法などの新しい方法があります。さらに一歩進んで、がん患者のQOLを向上させることが余命を延ばす1つと考えられ、「緩和ケア療法」が第5の治療法と位置づけられるようになってきました(図1)<sup>6)</sup>。がん治療は患者の全身状態に大きな影響を与えます。手術後は身体の回復が大変ですし、放射線療法や抗がん剤治療には多くの場合、さまざまな副作用